[Diagnosis of brain metastases: an update in 2012]
Emmanuèle Lechapt-Zalcman1, Marie Karanian-Philippe, Audrey Rousseau
1CHU de Caen, Laboratoire d'anatomie pathologique, avenue de la Côte-de-Nacre, 14033 Caen cedex 9, France. lechapt-e@chu-caen.fr
Abstract:
Diagnosis of brain metastases should aim to identify anatomoclinical entities for which a specific treatment is more accurate. Growing numbers of targeted therapies have shown to be effective against specific cancers. Several studies have reported that targeted therapies are capable of reducing brain metastases in melanoma or non small cell lung cancer (NSCLC), sometimes with a high dramatic response. These results have clearly impacted routine neuropathological practice, leading to multidisciplinary strategy management of brain metastases tissues. In accordance with the recommendations of French National Cancer Institute (INCa), the pathologist develops appropriate strategies for molecular and immunohistochemical analysis, in order to provide results as soon as possible.
Insights
Accurate diagnosis of brain metastases is crucial for effective treatment. Targeted therapies show significant promise in reducing brain metastases for specific cancers like melanoma and non-small cell lung cancer (NSCLC).
Area of Science:
- Oncology
- Neuropathology
- Molecular Diagnostics
Context:
- Brain metastases represent a significant challenge in cancer care.
- The advent of targeted therapies has revolutionized cancer treatment.
- Increasing evidence supports the efficacy of targeted agents in specific metastatic brain tumors.
Purpose:
- To highlight the importance of precise diagnosis for guiding targeted therapy selection in brain metastases.
- To underscore the impact of targeted therapies on neuropathological practice.
- To align diagnostic strategies with national recommendations for efficient patient management.
Summary:
- Diagnosis of brain metastases should identify specific entities amenable to targeted treatments.
- Targeted therapies have demonstrated high response rates in melanoma and non-small cell lung cancer (NSCLC) brain metastases.
- This necessitates a multidisciplinary approach and optimized molecular/immunohistochemical analysis by pathologists.
Impact:
- Enhanced diagnostic strategies are crucial for personalized treatment of brain metastases.
- Pathologists play a key role in facilitating the use of targeted therapies.
- Multidisciplinary management of brain metastases tissues is becoming standard practice.
